AstraZeneca plc (AZN) Given a GBX 4,700 Price Target at Morgan Stanley
AstraZeneca plc (LON:AZN) has been given a GBX 4,700 ($62.45) price objective by stock analysts at Morgan Stanley in a note issued to investors on Friday. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target would suggest a potential downside of 9.18% from the stock’s previous close.
AZN has been the topic of a number of other reports. Liberum Capital reiterated a “buy” rating and set a GBX 4,800 ($63.78) price target on shares of AstraZeneca plc in a research report on Tuesday, September 5th. HSBC Holdings plc increased their price target on shares of AstraZeneca plc from GBX 4,100 ($54.48) to GBX 4,150 ($55.14) and gave the company a “reduce” rating in a research report on Monday, October 9th. UBS AG set a GBX 4,550 ($60.46) price target on shares of AstraZeneca plc and gave the company a “neutral” rating in a research report on Thursday, August 31st. Jefferies Group LLC increased their price target on shares of AstraZeneca plc from GBX 4,350 ($57.80) to GBX 4,800 ($63.78) and gave the company a “hold” rating in a research report on Monday, September 11th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a GBX 5,700 ($75.74) price target on shares of AstraZeneca plc in a research report on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of “Hold” and an average price target of GBX 5,172.64 ($68.73).
AstraZeneca plc (AZN) traded down 0.21% during midday trading on Friday, reaching GBX 5164.00. 1,070,114 shares of the company’s stock were exchanged. The firm has a 50 day moving average of GBX 4,904.35 and a 200-day moving average of GBX 4,912.64. The stock’s market cap is GBX 65.38 billion. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00.
In other news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($58.07) per share, with a total value of £1,704.30 ($2,264.55).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.